APA (7th ed.) Citation

Bromberg, J. E. C., Issa, S., Bakunina, K., Minnema, M. C., Seute, T., Durian, M., . . . Doorduijn, J. K. (2019). Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): A randomised, open-label, phase 3 intergroup study. Lancet Oncology, 20(2), 216. https://doi.org/10.1016/S1470-2045(18)30747-2

Chicago Style (17th ed.) Citation

Bromberg, Jacoline E C., et al. "Rituximab in Patients with Primary CNS Lymphoma (HOVON 105/ALLG NHL 24): A Randomised, Open-label, Phase 3 Intergroup Study." Lancet Oncology 20, no. 2 (2019): 216. https://doi.org/10.1016/S1470-2045(18)30747-2.

MLA (9th ed.) Citation

Bromberg, Jacoline E C., et al. "Rituximab in Patients with Primary CNS Lymphoma (HOVON 105/ALLG NHL 24): A Randomised, Open-label, Phase 3 Intergroup Study." Lancet Oncology, vol. 20, no. 2, 2019, p. 216, https://doi.org/10.1016/S1470-2045(18)30747-2.